Login to Your Account

Intercept, Alimera, Amarin, Amag and more all lose ground on earnings

By Michael Fitzhugh
Staff Writer

Thursday, November 3, 2016

Shares of Intercept Pharmaceuticals Inc. fell 16.5 percent to close at $98.20 on Thursday as the company reported third-quarter revenue of $5.2 million, primarily attributed to its biliary cholangitis therapy, Ocaliva.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription